Abingworth closes Fund IV at $350m
The Anglo-American life sciences VC firm has exceeded the original $275m target for their Abingworth Bioventures IV fund (ABV IV), which was more than two times over-susbscribed.
16 January 2013•3 mins read
PEI INFRASTRUCTURE INVESTOR
Register to unlock this content
Daily global infrastructure news and market intelligence- Expertly curated insights that keep you ahead of the market
- Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
- Access to proprietary research and reports
- Selected investor strategy and competitor performance data